Table 4.
HR (95% CI) | p-value | ||
---|---|---|---|
Univariate analysis | |||
Tumor size | >20 mm vs. ≤20 mm | 2.83 (1.44–5.58) | <0.01 |
Node status | pN1-3 vs. pN0 | 5.54 (2.30–13.37) | <0.01 |
Ki67 | ≥14% vs. <14% | 1.40 (0.71–2.60) | 0.31 |
HER2 | pos vs. neg | 1.41 (0.55–3.65) | 0.48 |
Tumor grade | III vs. I + II | 1.49 (0.80–2.78) | 0.21 |
Age | 50–69 yrs. vs. <50 or ≥70 yrs. | 1.07 (0.56–2.05) | 0.84 |
Ghrelin intensity | 0 vs. 1 + 2 + 3 | 0.39 (0.18–0.88) | 0.01 |
Obestatin intensity | 0 vs. 1 + 2 + 3 | 0.38 (0.11–1.24) | 0.11 |
Multivariate analysis | |||
Tumor size | >20 mm vs. ≤20 mm | 1.78 (0.85–3.72) | 0.13 |
Node status | pN1-3 vs. pN0 | 4.52 (1.82–11.20) | <0.01 |
Ghrelin intensity | 0 vs. 1 + 2 + 3 | 0.38 (0.17–0.88) | 0.02 |
Hazard ratio (HR) and 95% confidence intervals (CI) obtained from Cox regression models. HER2, human epidermal growth factor receptor 2.